Form 4 Filing for Aprea Therapeutics, Inc.

This filing details transactions by John B. Henneman III, a director at Aprea Therapeutics, Inc. On June 16, 2026, Henneman acquired 3,135 shares of Common Stock at a price of $0.00 per share, bringing his post-transaction holdings to 13,364 shares. This acquisition is related to restricted stock units granted on the same date, which will vest on June 16, 2027, subject to continued service and potential acceleration. Additionally, Henneman was granted stock options to purchase 12,555 shares of Common Stock at an exercise price of $0.7293 per share. These options also vest in full on June 16, 2027, contingent upon continued service and subject to acceleration. Both the restricted stock units and the stock options represent direct ownership.